# Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

> **NCT00086957** · PHASE1,PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 31 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** docetaxel
- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00086957
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086957, "Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00086957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*